Lenalidomide (Revlimid, CC5013)

- Overview
  - Lenalidomide (Revlimid, CC-5013) is a derivative of thalidomide approved in the United States in 2005 for the treatment for myeloma and blood disorders called myelodysplastic syndromes. Lenalidomide has been used to successfully treat both inflammatory disorders and cancers in the past 10 years. There are multiple mechanisms of action, and they can be simplified by organizing them as mechanisms of action in vitro and in vivo.[29] In vitro, lenalidomide has three main activities: direct anti-tumor effect, inhibition of angiogenesis, and immunomodulation. In vivo, lenalidomide induces tumor cell apoptosis directly and indirectly by inhibition of bone marrow stromal cell support, by anti-angiogenic and anti-osteoclastogenic effects, and by immunomodulatory activity. Lenalidomide has a broad range of activities that can be exploited to treat many hematologic and solid cancers.
    
    Please contact us at for specific academic pricing.
- Properties
  - Categories
    
    Ligands for E3 Ligase
    
    CAS Number
    
    191732-72-6
    
    Molecular Formula
    
    C13H13N3O3
    
    Molecular Weight
    
    259.26
    
    Purity
    
    ≥98%
    
    Storage
    
    Powder: store in -20°C freezer for up to three years, store in 4°C freezer for up to two years
    In solvent: store in -80°C freezer for up to six months, store in -20°C freezer for up to two months
    
    Shipping
    
    Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
    
    SMILES
    
    O=C(C(N(CC1=C2C=CC=C1N)C2=O)CC3)NC3=O
    
    * For research use only

We Also Recommend

Lenalidomide hydrochloride

$244

Lenalidomide (Revlimid, CC5013)

We Also Recommend

Lenalidomide hydrochloride

Lenalidomide hydrochloride

Lenalidomide-OH

OICR-8268